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The olfactory receptor (OR) superfamily provides a basis for the remarkable ability to recognize and discriminate a large number of
odorants. Inmice, the superfamily includes1000members, and they recognize overlapping sets of odorantswith distinct affinities and
specificities. To address themolecular basis of odordiscriminationby themammalianORsuperfamily,weperformed functional analysis
on a series of site-directed mutants and performed ligand docking simulation studies to define the odorant-binding site of a mouse OR.
Our results indicate that several amino acids in the transmembrane domains formed a ligand-binding pocket. Although other G-protein-
coupled receptors (GPCRs) recognize biogenic ligands mainly with ionic or hydrogen bonding interactions, ORs recognize odorants
mostly via hydrophobic andvanderWaals interactions. This accounts for the broadbut selective bindingbyORs aswell as their relatively
low ligand-binding affinities. Furthermore, we succeeded in rational receptor design, inserting point mutations in the odorant-binding
site that resulted in predicted changes in ligand specificity and antagonist activity. This ability to rationally design the receptor validated
the binding site structure that was deduced with ourmutational and ligand docking studies. Such broad and specific sensitivity suggests
an evolutionary process during which mutations in the active site led to an enormous number of ORs with a wide range of ligand
specificity. The current study reveals themolecular environment of the odorant-binding site, and it further advances the understanding
of GPCR pharmacology.
Key words: computer modeling; G-protein-coupled receptor; ligand binding; mutation; odorant; olfactory receptor
Introduction
The vertebrate olfactory system has evolved the ability to recog-
nize and discriminate thousands of structurally diverse odorants.
A molecular basis for the detection of odorants was provided by
the discovery of the olfactory receptor (OR) superfamily, which is
a large family of multigenes that encode rhodopsin-like
G-protein-coupled receptors (GPCRs) (Buck and Axel, 1991).
The OR proteins are key players in the binding of odorants and
the conversion of chemical information into electronic signals in
olfactory neurons (Shepherd, 1994; Buck, 1996; Firestein, 2001;
Touhara, 2002; Mombaerts, 2004).
The current paradigmofOR–odorant interactions is based on
studies of a limited number of ORs that have been functionally
matched with their cognate ligands. Each odorant is recognized
by multiple ORs, whereas an individual OR can bind multiple
odorants with distinct affinities and specificities (Zhao et al.,
1998; Touhara et al., 1999; Wetzel et al., 1999; Araneda et al.,
2000; Kajiya et al., 2001); however, the mechanism of odorant
recognition by ORs was found to be more complex than this
model. Recent evidence indicates that someodorants cannot only
activate but also can inhibit ORs (Oka et al., 2004a,b). This dual
function of an odorant as an agonist and antagonist may provide
insight into the structure–function relationship of GPCRs in
general.
Multiple alignment analysis of the OR superfamily has al-
lowed identification of highly conserved and variable regions that
are likely to be involved in structural organization and ligand
recognition, respectively (Buck and Axel, 1991; Zhang and Fir-
estein, 2002). Some previous attempts, such as correlated muta-
tional analysis (Singer et al., 1996) and Fourier analysis of multi-
ple OR sequences (Pilpel and Lancet, 1999; Man et al., 2004),
further supported the hypothesis that variable residues are re-
sponsible for odorant binding (Lancet, 1986). Computer model-
ing strategy was first used for the rat OR5 using coordinates of
bacteriorhodopsin, a non-GPCR seven-transmembrane helix
protein (Singer and Shepherd, 1994; Singer et al., 1995), and later,
similar analyses were performed for two ORs, mouse S25 (puta-
tive hexanol receptor) (Floriano et al., 2000) and rat I7 (octanal
receptor) (Singer, 2000), based on the 7.5 Å rhodopsin structure
(Schertler, 1998). Most recently, using a 2.8 Å rhodopsin struc-
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ture (Palczewski et al., 2000), computermodeling and calculation
of lowest ligand-binding energy for several ORs were demon-
strated (Vaidehi et al., 2002; Floriano et al., 2004); however, pre-
vious analyses lacked functional studies to compensate for the
ambiguity of computer simulation and to validate the accuracy of
the prediction.
mOR-EG is a mouse OR that was isolated from an eugenol
(EG)-responsive olfactory neuron by Ca2 imaging and single-
cell RT-PCR (Kajiya et al., 2001). The response ofmOR-EG to EG
was recapitulated in a heterologous expression system using hu-
man embryonic kidney (HEK) 293T cells (Kajiya et al., 2001), as
well as in an in vivo system using transgenic mice (our unpub-
lished results). Recently, the odorant response assay using a Ca2
imaging technique was greatly improved such that 80% of
HEK293 cells transfected with mOR-EG and G15 responded to
EG (Katada et al., 2003). In addition to efficiency and reproduc-
ibility of the response assays, mOR-EG is an excellent OR for
systematic structure–activity relationship studies and computer
docking simulation. EG, one of the mOR-EG ligands, is a supe-
rior ligand to study because the functional groups are at fixed
positions on a benzene ring and it has fewer potential conforma-
tions, relative to aliphatic odorants. Finally, several competitive
antagonists have been identified for mOR-EG (Oka et al.,
2004a,b), providing a tool to investigate the molecular basis for
odorant recognition and the mechanism of subsequent receptor
dynamics.
In the current studies, we thoroughly examined the ligand
specificity ofmOR-EG.We found that this receptor recognizes 22
odorants that share certain molecular determinants, with EC50
values ranging from a fewmicromolar to several hundredmicro-
molar. We then attempted to elucidate the odorant-binding en-
vironment inmOR-EG and to determine how the ligand-binding
site confers such a broad but specific receptive range. Tomap the
odorant-binding site, we combined computational and muta-
tional analyses, resulting in a reliable structural model for OR–
odorant interactions. The critical finding in this report was the
ability to use the deducedmodel and site-directedmutagenesis to
rationally design an OR with a predicted specificity for agonists
and antagonists. The present study not only sheds light on the
molecular pharmacology of GPCRs in general but also on how
theOR family has evolved the ability to recognize such a variety of
chemical structures.
Materials andMethods
Materials and reagents. Odorant solutions were prepared as 1 or 3 mM
stocks in Ringer’s solution containing (in mM): 140 NaCl, 5.6 KCl, 2.0
CaCl2, 2.0 MgCl2, 5.0 HEPES, 2.0 sodium pyruvate, 9.4 glucose, and 1.25
KH2PO4, pH 7.4, and diluted to give the indicated concentrations before
experiments. EG was purchased from Nacalai Tesque (Kyoto, Japan), and
other odorants were obtained from Tokyo Kasei (Tokyo, Japan), Sigma-
Aldrich (St. Louis, MO), or T. Hasegawa (Tokyo, Japan). Isoproterenol hy-
drochloride was purchased from Nacalai Tesque. The mOR-EG (Kajiya et
al., 2001) is a mouse OR encoded by theMOR174–9 gene, according to the
nomenclature by Zhang and Firestein (Zhang and Firestein, 2002); see also
http://senselab.med.yale.edu/senselab/
ORDB/default.asp.
Ca2 imaging. HEK293 cells were grown in DMEM (Nacalai Tesque)
supplementedwith 10% fetal bovine serum (JRHBioscience). The trans-
fection and Ca2 imaging of HEK293 cells were performed using the
following procedure as described previously (Katada et al., 2003). Briefly,
the transfected cells were cultured for 24 h and loaded for 30min at 37°C
with 2.5 M fura-2 AM (Molecular Probes, Eugene, OR). Odorant solu-
tions were applied sequentially to the cells for 20 s, and a 3 min interval
between each odorant application ensured that the cells were not desen-
sitized as a result of the previous application of odorants. Fluorescence at
510 nm (excitation at 340 or 380 nm with a xenon lamp) was monitored
with an intensified CCD camera. An Argus-HiSCA calcium-imaging sys-
tem (Hamamatsu Photonics, Shizouka, Japan)was used to determine the
fluorescence ratio at 340 and 380 nm.
Molecular modeling of mOR-EG and mapping of a possible ligand-
binding pocket. The mOR-EG sequence was aligned with the bovine rho-
dopsin sequence (Palczewski et al., 2000) using Clustal W (version 1.8)
multiple alignment program (Thompson et al., 1994). The alignment
was refined manually based on the sequence motif information from the
OR family sequence (Zhang and Firestein, 2002) and the compatibility of
the amino acid position with the corresponding structure of the bovine
rhodopsin. Putative transmembrane regions inmOR-EGwere predicted
using the actual transmembrane regions of bovine rhodopsin. A three-
dimensionalmodel ofmOR-EGwas constructed using a homologymod-
eling approach incorporated in the program SegMod (Levitt, 1992) of
GeneMine (Lee and Irizarry, 2001). The conformations of the conserved
residues were kept in the mOR-EG model, and the other residues were
adapted according to the alignment. Because mOR-EG seemed to form
an eighth helix like that observed in the structure of rhodopsin (Katada et
al., 2004), the same structurewasmaintained in themOR-EGmodel. The
ligand binding site of mOR-EG was identified by cavity search of the
protein structure. One dot per angstrom of grid was sited in mOR-EG,
and an open site cut-off value (7.0 Å) was used to find acceptable cavities.
Sphere clusters were generated for the whole receptor, and cavities
smaller than the 50.0 point were cut off. This allowed identification of six
acceptable cavities in the receptor. One of these covers the extracellular
portion of the receptor, as well as two-thirds of the inside of the helical
barrel. This is a location similar to the established ligand-binding pockets
of other GPCRs.
Docking simulation of the receptor–ligand complexes. Automatic dock-
ing was performed with the AS-Dock program on Molecular Operating
Environment (MOE) (Chemical Computing Group) (Kataoka and
Goto, 2002). AS-Dock docking consists mainly of three steps: generating
conformations of ligand, shape fitting on receptor surface, and energy
minimization. A maximum of 2000 conformations per ligand were gen-
erated by the stochastic conformation search method and stored into a
database file if no duplicate was found with the root mean square (rms)
tolerance (cut-off 0.5 Å). Every conformation of a ligand was placed in
the promising binding cavity site comprising three helices (TM3–5–6) by
superimposing it onto a grid sphere site. Each ligand–receptor complex
model generated in a previous step was subsequently subjected to refine-
ment using the molecular mechanics minimization protocol and the
MMFF94x force field (Halgren, 1996a,b,c,d,e) in MOE. In the minimi-
zation step, structural flexibilities of both ligand and side-chain atoms in
the residues within 4.5 Å around the grid sphere site were allowed. The
distance-dependent dielectric constant and distance cut-off (8–10 Å)
were used for nonbonded interaction energy calculation. Energy mini-
mization was terminated when the rms gradient fell below the cutoff
value (0.001 Å). The total energy was calculated from the sum of ligand–
receptor interaction energy (electrostatic and van der Waals) and intra-
energy of ligand molecule. The resulting ligand structures were aligned
according to total energy, and the first structural cluster (each structural
member was within 10 kcal/mol from the lowest energy structure) was
considered as a candidate ligand–receptor complex.
Site-directed mutagenesis. Mutations were introduced into mOR-EG
cDNA using the QuickChange site-directed mutagenesis kit (Stratagene,
La Jolla, CA). All of the single mutation products were digested with
EcoRI and XhoI, and fragments were inserted into the EcoRI–XhoI site of
the Flag-rho-pME18S vector. All mutations were confirmed by DNA
sequencing, using a BigDye Terminator v3.1 Cycle Sequencing kit (Ap-
plied Biosystems, Foster City, CA).
cAMP assay. Transfection of and cAMP assay in HEK293 cells was
performed using the following procedure as described previously
(Katada et al., 2003). Briefly, the mOR-EG-transfected cells were cul-
tured for 24 h and incubated further for 30 min with 1 mM 3-isobutyl-1-
methylxanthine (IBMX). The cells were exposed to the indicated concen-
tration of odorant solution containing 1mM IBMX for 15min. The levels
of cAMP were determined using an enzyme immunoassay kit (Applied
Biosystems).
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Figure 1. Representative Ca 2 responses and dose–response profiles for various ligands in HEK293 cells expressing mOR-EG and G15. Pseudocolored images and Ca
2 response profile 24 h
after transfection in a representative singleHEK293 cell that transiently expresses Flag-rho-taggedmOR-EG andG15. Odorants (100M)were applied for 20 s at the times indicated by arrowheads.
Red cells indicate high levels of intracellular Ca 2measured by fluorescent ratio intensities, andblue cells represent the basal levels. The series of odorantswere divided into three groups: in the first
group, R3–OCH3, R4–OH, andR1 is variable (A); in the secondgroup, R1–CHO, R4–OH, andR3 is variable (B); and, in the third group, R1–CHO, R3–OCH3or–CH3, andR4 is variable
( C). The dose–response and EC50 values for each odorant are also shown. Each point represents the mean SE from 50–90 cells in a representative experiment from three to five replicates.
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Immunoprecipitation andWestern blot analyses. Immunoprecipitation
andWestern blot analyses were performedusing the following procedure
as described previously (Katada et al., 2003). Briefly, mOR-EG-
transfected cells were lysed and immunoprecipitated with anti-Flag
monoclonal antibodies (Sigma-Aldrich). The immunoprecipitated sam-
ples were separated on a 12% SDS-polyacrylamide gel and then trans-
ferred electrophoretically onto a polyvinylidene difluoride membrane.
The membrane was blocked with 5% skim milk in Tris-buffered saline
(150mMNaCl, 30mMTris-HCl, pH 7.5) with 0.1%Tween 20 (TBST) for
1 h and then incubated with anti-Flag polyclonal antibody (1:1000 dilu-
tion in TBST) for 1 h. After a 1 h incubation with 1:10,000 anti-rabbit
IgG–alkaline phosphatase conjugate (Promega, Madison, WI) in TBST,
signals were detected by applying nitroblue tetrazolium and 5-bromo-4-
chloro-3-indolyl-phosphate (Promega).
Flow cytometric analysis. Flow cytometric analysis was performed us-
ing the following procedure as described previously (Katada et al., 2004).
Briefly, mOR-EG-transfected cells were washed once with PBS and
stripped off from the dish with PBS containing 5 mM EDTA. The cells
were then labeled with anti-Flag antibodies and Alexa Fluor 488 anti-
mouse IgG and then applied to a FACS Calibur instrument (Becton
Dickinson,Mountain View, CA). Approximately 10,000 events were col-
lected. Histograms were generated using CELLQuest software (Becton
Dickinson).
Results
Determination of the molecular receptive range of mOR-EG
in the Ca2 imaging assay
Several functional assays using various homologous and heterol-
ogous expression systems have been developed for examining
odorant responsiveness (Mombaerts, 2004). Among these assays,
Ca2 imaging in HEK293 cells coexpressing the promiscuous
G-protein, G15, is a reliable high-throughput system that allows
for determination of the dose dependence of odorant–OR inter-
actions (Kajiya et al., 2001; Katada et al., 2003). To construct a
structure–activitymatrix formOR-EG,we tested a series of odor-
ants based on the structure of known mOR-EG ligands, EG (Fig.
1A, compound 4) and vanillin (compound 5), with variations at
the R1, R3, and R4 positions on the benzene ring (Kajiya et al.,
2001). Figure 1 shows pseudocolored images and a representative
profile of Ca2 responses to a systematic array of odorants (100
M) in HEK293 cells expressing mOR-EG and G15. We also
Figure2. Odorant responsiveness andprotein expression levels in Ser113mutants.A, Dose–response of Ser113 andSer210mutants for odorants as obtained fromCa 2 imaging analyses. Ca 2
measurementswere performed 24 h after transfectionwith eachmutant to generate dose–response curves. Each point represents themean SE from 60–90 cells in a representative experiment
from four to eight replicates. Percentages were calculated from the increase in the ratio induced by 300M EG in cells expressing wild-typemOR-EG. B, EG-induced cAMP increases in HEK293 cells
expressing a series of Ser113mutants. The fold increases were calculated based on cAMP levels inmock-transfected HEK293 cells that were stimulatedwith 300M EG. The data are representative
of four independent experiments. C, Immunoblot analyses of Flag-rho-taggedmOR-EG and a series of tagged Ser113mutants 48 h after transfection. The arrow indicates the bands originating from
mOR-EG andmutant receptors. Therewas no obvious difference in the protein expression level.D, Flow cytometric analysis ofwild-typemOR-EG and S113Vmutant andquantification of the amount
of receptors expressed on the cell surface. Unpermeabilized HEK293 cells transfected with Flag-rho-tagged mOR-EG or S113V mutant were labeled with anti-Flag monoclonal antibodies and
analyzed for surface expression. Filled gray bars represent flow cytometric profiles of control mock-transfected cells, and unfilled black bars represent the flow cytometric profiles for wild-type
mOR-EG or the S113Vmutant. The flow cytometric profiles for each OR andmock-transfected cells are superimposed. A slight right shift was observed with both the wild-type mOR-EG and S113V
mutant, demonstrating that they are equally expressed on the cell surface.
Table 1. Amino acids in the predicted binding pocket
Location Residues
TM3 Phe 102 Phe 105 Cys 106 Phe 108 Val 109
Glu 112 Ser 113 Leu 116
EC2 Glu 181 Phe 182
TM5 Thr 205 Phe 206 Asn 207 Ser 210 Thr 211
Leu 212 Ile 215
TM6 Ala 248 Ile 251 Phe 252 Thr 255 Ile 256
Phe 258 Leu 259
TM7 Thr 280 Ile 283
A total of 26 amino acids are shown. Ten amino acids predicted to interact with EG are shown in bold type.
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examined the dose dependence for odorants that could stimulate
mOR-EG.
The first series of odorants possessed an ether group (–OCH3)
and a hydroxyl group (–OH) at the R3 and R4 positions, respec-
tively, with variable groups at the R1 position (Fig. 1A). The
binding pocket accommodated awide range of functional groups
at the R1 position, but a charged group, such as carboxyl acid or
an amine, was not acceptable. Interestingly, odorants possessing
a propenyl group at the R1 position tend to become antagonists
(Oka et al., 2004a,b), suggesting thatmOR-EGaccepts a variety of
functional groups at the R1 position but also discriminates be-
tween the subtle structural differences of, for example, an allyl
group and a propenyl group.
The second series of odorants possessed an aldehyde group
(–CHO) and –OH at the R1 and R4 groups, respectively, with
variable groups at R3 (Fig. 1B). EC50 values increasedwith the size
of R3, for example, 4 M for R3 a methyl group (–CH3) (com-
pound 15), 26 M for R3 –OCH3 (compound 5), and 215 M
for R3 –OCH2CH3 (compound 16), whereas no response was
observed for R3 –OH (compound 14) or –H (compound 13).
These results suggest that the size of R3 and possibly hydrophobic
interactions are important determinants for agonist activity. Fi-
nally, 4-hydroxy-3-methyl benzaldehyde (compound 15)was the
most potent agonist for mOR-EG among the odorants tested in
this study.
The third series of odorants possessed –CHO at R1 and either
–OCH3 or –CH3 at R3, with variable groups at R4 (Fig. 1C). Rel-
atively small differences in EC50 values were observed among
odorants with changes in R4, suggesting that mOR-EG is rela-
tively tolerant to the functional group at this position; however,
little or no response was observed when R4 was –CH3 (com-
pound 21) or –H (compound 20). Thus, the presence of an oxy-
gen atom attached to the benzene ring seems to be required for
binding activity, which implies that electrostatic interactions
might be involved at this position.
The orientation of three substituted groups on the benzene
ring turned out to be critical. Thus, mOR-EG did not respond to
vanillin isomers such as isovanillin (R1 –CHO, R3 –OH, and
R4 –OCH3) and o-vanillin (R1 –CHO, R2 –OH, and R3
–OCH3). Furthermore, a lack of one of the functional groups or
an addition of an extra functional group (compounds 1, 13, and
20) resulted in a complete loss of activity. Systematic analysis of
the structure–activity relationship revealed that mOR-EG has a
broad but selective molecular receptive range.
Molecular modeling of mOR-EG and analysis of
ligand docking
We next constructed a molecular model of mOR-EG. We based
this model on the atomic-level crystal structure of bovine rho-
dopsin (Palczewski et al., 2000) because ORs appear to be mem-
bers of the class A rhodopsin-like GPCR family. Multiple se-
quence alignment using Clustal W (Thompson et al., 1994)
deduced putative transmembrane regions in mOR-EG, and a
three-dimensional structuralmodel ofmOR-EGwas constructed
using the homologymodeling approach incorporated in the Seg-
Mod (Levitt, 1992) of GeneMine (Lee and Irizarry, 2001). A cav-
ity search using the binding-site module of Insight II (Accelrys
Software Inc.) revealed a putative odorant-binding pocket made
up of 26 amino acid residues (Table 1). Docking analysis was
performed for several mOR-EG ligands using the docking mod-
ule of MOE, demonstrating multiple candidate structures for a
ligand–mOR-EG. LIGPLOT scoring (Wallace et al., 1995) of both
hydrogen bonds and hydrophobic contacts for various ligands
suggested that the 10 amino acids set in bold in Table 1were likely
candidates for being involved in odorant recognition.
Site-directed mutations in amino acids with a polar side chain
(Ser, Thr, and Asn)
To determine the role of these 10 amino acids, they were targeted
for site-directed mutagenesis and then analyzed in a functional
assay of odorant binding. EG was used for functional analysis of
mutated mOR-EGs because EG has been shown to be a cognate
ligand of mOR-EG in olfactory neurons in vivo (Kajiya et al.,
2001; Oka et al., 2004a; our unpublished results). The docking
simulation suggested that Ser113, Asn207, and Thr255 had a
good chance of making a hydrophilic interaction with a ligand
through hydrogen bonding. To evaluate this computer predic-
tion experimentally, Ser113 was mutated to Thr, Cys, Val, or Ala.
Responsiveness to EG was examined by Ca2 imaging in
HEK293 cells coexpressing a mutant receptor and G15. Both
S113T and S113C exhibited responses to EG with a somewhat
altered EC50 value (17 and 889 M, respectively) compared with
thewild-typemOR-EG (47M) (Fig. 2A). In contrast, S113A and
S113V completely lost the ability to respond to EG in the Ca2
assay (Fig. 2A). In addition, these two mutants were unable to
respond to the odorants tested in Figure 1. Without G15, stimu-
lation of wild-type mOR-EG or S113T resulted in a robust in-
crease in cAMP, but an increase in cAMP was not observed for
S113V and S113A (Fig. 2B), a finding consistent with the Ca2
Table 2. Effect of point mutations of mOR-EG on EC50 values obtained from the
Ca2 response assay
Mutant EC50 (M) EC50 wild/EC50 mut n
TM3 F105L 36 13 1.2 3
V109A 38 15 1.2 4
V109L 42 22 1.1 6
S113A No response 0 7
S113V No response 0 8
S113T 17 6 2.8 4
S113C 889 461 0.05 4
TM5 T205A 58 12 0.7 3
T205V 36 16 1.3 4
T205S 48 21 1.0 3
F206L 107 18 0.5 4
N207A No response 0 7
N207Q No response 0 8
N207D No response 0 8
S210A 38 11 1.2 5
S210T 26 13 1.8 4
S210C 32 11 1.5 4
T211A 169 62 0.3 3
T211V 107 35 0.4 4
T211S 41 11 1.2 3
L212V 384 172 0.1 4
TM6 I251L 40 10 1.2 3
I251V 43 10 1.1 4
F252L 235 81 0.2 4
T255A 157 75 0.3 3
T255V 78 27 0.6 3
T255S 38 12 1.2 3
I256L 406 115 0.1 3
I256V 57 34 0.8 3
L259V 235 68 0.2 4
TM7 T280A 47 16 1.0 4
T280V 54 11 0.9 3
T280S 41 11 1.1 3
Wild type 47 17 5
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imaging results. Western blot and flow cytometric analyses
showed that there was no significant difference between the ex-
pression of wild-type and mutant receptors on the cell surface,
suggesting that the complete loss of odorant responsiveness was
not caused by the membrane mistargeting of the mutant recep-
tors (Figs. 2C,D). Mutation of Ser210, which resides in the bind-
ing pocket but does not appear to interact with ligands in the
docking simulation, did not affect the responsiveness to EG (Fig.
2A). These results support the idea that Ser113 acts as hydrogen
donor for the formation of a hydrogen bondwith an oxygen atom
at R4, which is a bond that appears to be crucial for agonist activ-
ity. The S113T mutant appeared to increase the hydrophilic in-
teractionswith a ligand, and thus, the EC50 value decreased2.8-
fold. In contrast, the EC50 for the S113C mutant was 10-fold
higher, which corresponds with the fact that Cys is not a good
hydrogen donor (Table 2).
We next tested a series of mutations at Thr residues placed in
the predicted odorant-binding pocket: Thr205 (TM5), Thr211
(TM5), Thr255 (TM6), and Thr280 (TM7), each of which was
replacedwith Ser, Val, or Ala. In contrast to Ser113, theVal or Ala
mutation at Thr211 and Thr255 did not abolish the responsive-
ness to EG, indicating that these residues are not involved in
electrostatic interactions but rather in van derWaals interactions
(Fig. 3A). Also, themutation at Thr205 and Thr280 did not affect
the responsiveness, indicating that these residues are not involved
in EG recognition (Fig. 3A).
The docking analysis predicted that Asn207 was involved in
both electrostatic and hydrophobic interactions with the ligand.
N207Q and N207D mutations completely abolished Ca2 re-
sponses to EG, although the protein expression level on the cell
surface was unaltered based on Western
blot and flow cytometric analyses (data
not shown). Because the response activity
was completely impaired, we could not de-
termine whether Asn207 was involved in
ligand binding or in proper receptor fold-
ing. Interestingly, a recent report showed
thatOR-directed neuronal guidance to the
olfactory bulb was sensitive tomutation of
Asn205 in M72, another mouse OR
(Zheng et al., 2000). Because this residue
corresponds to Asn207 in mOR-EG, it
may provide contextual information in the
receptor structure for defining the ligand-
binding specificity by mOR-EG (Feinstein
and Mombaerts, 2004). Importantly, this
position is highly variable in theOR super-
family, also supporting the idea that it
helps define ligand specificity.
Site-directed mutations in hydrophobic
amino acids (Leu, Ile, Val, and Phe)
It appears that there are many hydropho-
bic amino acids, such as Leu, Ile, Val, and
Phe, in the predicted binding pocket.
These probably provide a hydrophobic en-
vironment that accommodates relatively
small aliphatic molecules such as odor-
ants. Figure 3B shows the effects of muta-
tions in these residues on the responsive-
ness to EG in the Ca2 imaging assay. We
mutated Leu to Val, Ile to Leu or Val, Val
to Ala or Leu, and Phe to Leu because all of
these substitutions provide aminimal change in size and polarity.
L212V and L259V substitutions resulted in a one-order of mag-
nitude increase in the EC50 value, suggesting that Leu212 and
Leu259 are involved in van der Waals interactions with the li-
gand. The I251L and I251V mutants responded to EG with the
sameEC50 value as thewild typemOR-EG,whereas I256L but not
I256V showed a reduction in responsiveness. This suggested that
Ile256 is located in close proximity to the ligand and is responsi-
ble for defining the spatial configuration of the binding pocket. A
mutation at V109 and Phe105 did not affect the responsiveness to
EG, whereas the EC50 values for F206L and F252L increased two-
and fivefold, respectively, suggesting that Phe206 and Phe252 are
likely involved in ligand recognition, as predicted by the docking
simulation.
Binding of EG in the binding site and the orientation of
adjacent amino acids
Figure 4A shows the structure for EG bound in the binding site
that is most consistent with the experimental results and the
docking analyses. Ser113 serves as a hydrogen donor and forms a
hydrogen bondwith an oxygen atomattached to the benzene ring
at the R4 position, an interaction necessary for agonist activity
(Fig. 1C). Amino acids predicted by themutation experiments to
interact with EG, such as Asn207, Leu212, Leu259, Thr211,
Thr255, Ile256, Phe206, and Phe252, are all located in close prox-
imity to EG in the defined structure (Fig. 4A). Interestingly,
roughly half of the binding pocket resided in the lipid bilayer, and
the amino acids in the binding site are not conserved among the
OR family (Fig. 4B). This variability is consistent with their role
in providing a range of molecular receptivity for the ORs.
Figure 3. Responsiveness to EG of a series of site-directedmutants. A, Dose–response curves obtained from Ca 2 imaging of
HEK293 cells expressing receptors mutated at various Thr residues. Thr was mutated to Ser (purple triangle), Val (green inverted
triangle), or Ala (red diamond). B, EG dose–responses of mutants at hydrophobic amino acids. Leu was mutated to Val (green
inverted triangle), Ilewasmutated to Leu (purple triangle) or Val (inverted green triangle), Valwasmutated to Ala (red diamond)
or Leu (purple triangle), and Phe was mutated to Leu (inverted purple triangle).
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Design of a receptor with a predicted
ligand specificity
Based on the bindingmodel, we attempted
to rationally design a receptor to deter-
mine whether specific point mutations
would affect ligand specificity as predicted.
Although Val109 appears to reside in the
binding pocket, V109A or V109L substitu-
tions do not affect the responsiveness to
EG, suggesting that this residue does not
make strong hydrophobic interactions
with EG; however, we noticed that the
score of the hydrophobic interaction be-
tween Val109 with other ligands, such as
ethyl vanillin (EV) (compound 16) and
3,4-diethoxy benzaldehyde, was larger
than that with EG. Indeed, Val109 was lo-
cated in close proximity to a methoxy
group at the R3 position of EG. Therefore,
EV should interact more strongly with
Val109 than EG because EV has a bulkier
ethoxy group. This also suggests that the
fivefold higher EC50 for EV is caused by the
steric effect of Val109.
We therefore reasoned that mutation
of Val109 to Ala (V109A) would reduce
the EC50 value for EV. In contrast, the EC50
valueofV109L forEVshouldbecomehigher
because Ala has less bulk and fewer steric in-
teractions than Leu (Fig. 5A). In fact, we
found that thesemutations affected theEC50
values as predicted. Thus, the EC50 values of
V109A andV109L for EG and 4-hydroxy-3-
methyl benzaldehyde (compound 15) were
the same as for the wild-type mOR-EG,
whereas the EC50 value for EV was twofold
lower for V109A and twofold higher for
V109L. Stronger effects were observed using
3,4-diethoxy benzaldehyde, an agonist that
possesses an ethoxy group at positions R3
andR4: theEC50 value forV109Awas sixfold
lower than thewild type, whereas V109L did
not show any response to 3,4-diethoxy ben-
zaldehyde (Fig. 5B). These results suggest
that V109 is located in close proximity to the
R3positionand that the sizeof the functional
group at position R3 is one of the determi-
nants of ligand potency. Most importantly,
these observations validated the ligand binding model of mOR-EG
that we had deduced based on themutational studies.
Elucidation of a mode of antagonist binding
We recently identified three competitive antagonists for mOR-
EG: methyl isoeugenol (MIEG), isosafrole, and oxidatively
dimerized isoeugenol (Oka et al., 2004a,b). A propenyl group of
EG at the R1 position appears to be a prerequisite for antagonist
activity (Oka et al., 2004b). The orientation of EG in the binding
site is such that Phe252 is located near the allyl group of EG (Figs.
4A, 5A). We therefore hypothesized that interactions of Phe252
with a functional group at position R1 are involved in ligand
binding and subsequent receptor dynamics during transition
from an inactive to an active state. Thus, we reasoned that a
mutation at Phe252 might affect antagonist activity. Indeed,
MIEG did not inhibit the responsiveness of F252L to EG (Fig. 6).
Also, T255V or V109A, which are mutations in residues just
above Phe252 or near the R3 position in the binding site, showed
the same antagonist sensitivity as the wild-typemOR-EG (Fig. 6).
These results confirmed that Phe252 is located near the R1 posi-
tion, which is consistent with the binding model, and they re-
vealed that Phe252 is involved in antagonist recognition. Finally,
an intriguing possibility is that Phe252 makes – interactions
with a double bond of the propenyl group that is conjugated with
the benzene ring. This could block conformational changes,
keeping the receptor in an inactive state.
Discussion
In this study, we experimentally determined the odorant-binding
site that confers the broad but selective ligand spectrum of the
Figure 4. Amodel for binding of EG tomOR-EG and the orientation of amino acids in the binding site.A, Side view of EG bound
tomOR-EG. Ser113 forms a hydrogen bondwith an oxygen atomattached to the benzene ring at the R4 position (red dotted line).
The orientation of amino acids in the binding site is shown, including Ser113, Phe206, Asn207, Thr211, Leu212, Phe252, Thr255,
and Leu259. TMIII, V, and VI are shown as yellow ribbons. B, Location of amino acids in the binding site. Red, Variable amino acids
in the OR family; blue, conserved amino acids in the OR family. Mutations in amino acids highlighted by the pink circle cause a
significant (5-fold) change in EC50 values; for those highlighted with a yellow circle, the EC50 value was modestly (5-fold)
affected; and for those indicated with a black circle, the EC50 value was not affected.
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G-protein-coupled OR superfamily. We found that most of the
critical residues involved in odorant recognition, and therefore
sensitive to mutation, were hydrophobic and that the binding
pocket was in the space formed by TM3, TM5, and TM6. The
accuracy of the binding model that we deduced was validated by
the fact that single amino acid changes caused predictable
changes in ligand specificity. Based on the effects ofmutations on
antagonist activity, we further identified an amino acid in TM6
that was involved in receptor dynamics involved in transition
from an inactive to an active conformation. The combination of
functional experimental analysis and computational docking
simulation strongly suggests the molecular basis of the
structure–activity.
Because the GPCR families are major targets of therapeutic
agents (Hopkins and Groom, 2002), many
studies have focused on the molecular ba-
sis by which they bind agonists. Molecular
modeling based on the atomic-level struc-
ture of a rhodopsin (Palczewski et al.,
2000) and a wealth of mutational studies
have revealed how ligands, such as hor-
mones and neurotransmitters, bind seven-
transmembrane GPCR proteins (Rivkees
et al., 1999; Church et al., 2002; Manivet et
al., 2002; Berkhout et al., 2003). It has been
difficult to design agonists or antagonists
based on the binding model, however, be-
cause receptor activation seems to also in-
volve complex conformational changes.
OR–odorant interactions should be an ex-
cellent model system for understanding li-
gand binding by GPCRs because each OR
possesses a broad but specific ligand spec-
ificity and because ORs comprise the larg-
est multigene family that belongs to the
well characterized rhodopsin family of
GPCRs (Bockaert and Pin, 1999).
The nature of the receptor sites that
provide the molecular basis of olfactory
discrimination has been argued over the
years. The stereospecific receptor theory
proposed by Amoore (1963) and others
has been validated by the discovery of the
OR superfamily and subsequent experi-
mental functional evidence (Buck and
Axel, 1991; Zhao et al., 1998; Touhara et
al., 1999;Wetzel et al., 1999; Araneda et al.,
2000; Kajiya et al., 2001). Physiological ex-
periments also suggested that each func-
tional group or “odotope,” in analogy to a
pharmacophore or epitope, was a molecu-
lar determinant for the ability of odorants
to act as ligands for an OR (Shepherd,
1994). Our results provide direct insight
into the nature of odorant–OR interac-
tions at the molecular level and provide
evidence for a steric and functional
odotope theory. The most revealing find-
ingwas that amutation in the site that con-
trols the ability of mOR-EG to distinguish
different sizes of odorant molecules leads
to an expected change in ligand specificity.
We targeted Val109 for this strategy, re-
sulting in successful rational receptor design. We further showed
that ligand information or determinants were transduced by the
three-dimensional configuration of the binding pocket and its
specific odorant ligand. Together, these results allowed a full un-
derstanding of the molecular basis for odorant detection.
Our results revealed that nine amino acids in TM3, TM5, and
TM6 were involved in odorant recognition by mOR-EG (Fig. 7).
One of the critical residues is Ser113, which serves as a hydrogen
donor to provide a hydrogen bond with a ligand. Consistently,
recent computational studies based on computer modeling and
calculation of lowest ligand-binding energy for several ORs
showed that a Ser residue in TM3 serves as the anchor point for a
ligand such as an aliphatic alcohol (Floriano et al., 2004). In
another work, a set of 22 amino acid positions have been pre-
Figure5. OrientationofVal109 in thebindingpocket and ligand specificity ofV109LandV109Amutants.A, Topviewof theEG-
and EV-boundmOR-EG structures. EG and EV are shown in blue and pink, respectively. Ala109 and Leu109 in Val109mutants are
shown in green.B, Ca 2measurementswere performed24h after transfection of each receptor, and dose–response curveswere
generated for EG, 4-hydroxy-3-methoxy benzaldehyde, EV, and 3,4-diethoxy benzaldehyde. The EC50 values of EV for V109L and
V109Awere 407 and75M, respectively,whereas the EC50 value ofwild-typemOR-EG for EVwas 215M. TheV109Lmutantwas
unresponsive to 3,4-diethoxy benzaldehyde, whereas the EC50 values for the V109A mutant and the wild-type mOR-EG were 60
and 500M, respectively.
Figure6. Effects ofmutations on the antagonist activity ofMIEG. Dose-dependent inhibition of EG-induced Ca 2 increases by
MIEG, an antagonist for mOR-EG, was observed for wild-typemOR-EG and the V109A and T255Vmutants, but inhibition was not
observed for the F252Lmutant. EG (300M) in thepresenceor absenceof 3000, 1000, or 300MMIEGwas applied for 20 s to each
of the receptor-expressing HEK293 cells at the time indicated by the arrowhead. EG-induced Ca 2 increaseswere shown for each
mutant as a percentage of the Ca 2 increases induced by 300M EG in the absence of MIEG.
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dicted to form the odorant-binding pocket
ofORs, based onhigh conservation among
orthologs and variability among paralogs
(Man et al., 2004), four of which were
matched with our predicted residues.
The spatial location of the odorant-
binding pocket was similar to that for
other biogenic GPCRs (Rivkees et al.,
1999; Church et al., 2002; Manivet et al.,
2002; Berkhout et al., 2003) (Fig. 4A);
however, the environment of the odorant-
binding site in an OR was different from
that in other GPCRs (Fig. 7). For example,
catecholamines have been shown to form
multiple electrostatic interactions with ad-
renergic receptors (ARs) (Klabunde and
Hessler, 2002). Isoproterenol possesses
two aromatic hydroxyl groups and one
secondary amine that is conserved in the
biogenic amines, and each of these form ahydrogen bond or a salt
bridge with the receptor (Wieland et al., 1996). The associative
strength of these ionic bonds is greater and the interaction more
rigid than those that of hydrophobic or van der Waals interac-
tions, and it accounts for high-affinity ligand binding. In con-
trast, hydrophobic amino acids in the odorant binding site ap-
pear to play critical roles in odorant recognition (Fig. 7). Because
of the weaker association via hydrophobic interactions, OR li-
gands exhibit relatively high EC50 values in comparison with li-
gands for other GPCRs (Watson, 1994). Nonetheless, the recog-
nition of odorants by ORs is still selective for shape, size, and
length of a ligand, and this selectivity is determined by the envi-
ronment of the binding site in each OR.
Mutational studies demonstrated that a subtle difference in
the binding site of an OR affected odorant responsiveness. Such
sensitivity implicates an evolutionary process for creating a diver-
sity of odorant-sensing residues, because many of the amino ac-
ids that participate in ligand recognition appear to be variable in
the OR family. Amino acid variations resulting from positive
selection during the evolutionary process have also been found in
major histocompatibility complex class I molecules, wherein the
variability is found mainly in the antigen recognition site
(Hughes and Nei, 1988). Furthermore, the high proportion of
pseudogenes and an unusually high rate of single nucleocide
polymorphisms occurred in human OR genes (Lapidot et al.,
2001). Mutations in functional ORs would affect the variation in
the sense of smell of humans and some of the specific amosmias.
Activation of a GPCR involves complex conformational
changes from an inactive to an active formduring ligand binding.
It has been reported that during ligand binding, TM6 in some
GPCRs undergoes a movement that unlocks a network of ionic
interactions in the cytoplasmic ends of TMs, which in turn leads
to the activation of downstream signaling cascades (Javitch et al.,
1997; Ballesteros et al., 2001; Spalding and Burstein, 2001; Saam
et al., 2002). Consistently, Phe252 in TM6 ofmOR-EG appears to
be critical in switching the receptor conformation from an inac-
tive to an active state. Phe252 likely forms a stable interaction
with an antagonist and helps tomaintain the receptor conforma-
tion in the inactive state. Preliminary results showed that an
A248Gmutant in TM6 caused a reduction in the amplitude of the
maximal Ca2 responses with no change in the EC50 value (our
unpublished observations), further supporting the idea that TM6
is involved in receptor activation.
In summary, our experimental evidence revealed that the
odorant-binding site of an olfactory receptor lies in a hydropho-
bic pocket formed by TM3, TM5, and TM6, which provides the
molecular basis for the broad but selective ligand spectrum of an
OR.Our results suggest that the ligand specificity of anOR can be
manipulated by point mutations in the binding site, allowing the
OR to acquire the ability to recognize certain odorant molecules
with higher affinities and others with lower affinities. In addition,
it is possible to design an odorant that fits better in the binding
site, which could eventually lead to the development of new,
commercially useful scents or flavors. Finally, systematic muta-
tional analysis, like that performed in the current study, will be a
powerful tool for exploring the dynamics ofGPCRs during ligand
binding and should help in the development of therapeutic
applications.
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